| Literature DB >> 2869722 |
A F Bencini, A H Scaf, Y J Sohn, C Meistelman, A Lienhart, U W Kersten, S Schwarz, S Agoston.
Abstract
The effect and plasma concentrations of vecuronium bromide were measured in normal patients after an intravenous dose of 50, 100, or 150 micrograms/kg and in patients with renal failure after 50 or 100 micrograms/kg. Urinary excretion of vecuronium was studied in normal patients after the 150 micrograms/kg dose. Pharmacokinetic parameters of patients with or without renal failure were similar. No metabolites of vecuronium were found in the plasma. Twenty percent of vecuronium was excreted unchanged in the urine; 5% as the 3-hydroxy derivative. No other metabolites of vecuronium were found in the urine. Increasing doses of vecuronium shortened the onset, but prolonged the duration of action and the recovery rate, to a similar extent in patients with or without renal failure. It was concluded that the disposition of vecuronium was best described by a three compartment model. Both the disposition and the effect of vecuronium are only marginally disturbed by renal failure.Entities:
Mesh:
Substances:
Year: 1986 PMID: 2869722
Source DB: PubMed Journal: Anesth Analg ISSN: 0003-2999 Impact factor: 5.108